Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa

Hidradenitis suppurativa (HS) is a chronic skin disease characterized by recurrent painful inflamed nodules/abscesses and draining fistulas that negatively impact quality of life. Adalimumab, a monoclonal antibody against tumor necrosis factor‐α, has been approved in the EU, USA and Japan for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Akimichi, Takahashi, Hidetoshi, Ozawa, Kentaro, Imafuku, Shinichi, Nakama, Takekuni, Takahashi, Kenzo, Matsuyama, Takashi, Okubo, Yukari, Kitamura, Susumu, Matsuda, Naoto, Zhao, Yiwei, Yokoyama, Masayuki, Hayashi, Nobukazu, Terui, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771639/
https://www.ncbi.nlm.nih.gov/pubmed/31282051
http://dx.doi.org/10.1111/1346-8138.14997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771639/
https://www.ncbi.nlm.nih.gov/pubmed/31282051
http://dx.doi.org/10.1111/1346-8138.14997

Ejemplares similares